PTX Capital — 2025 Investments
1 investments dated 2025 · listed companies and verified rows first · show all
Infinity Bio provides immune system analysis through its proprietary MIPSA antibody reactome profiling platform, which identifies the targets of individual immune responses against human viruses, human proteins (autoimmunity), and allergen proteins.
BiotechDeep TechHealthtechBaltimore, US
Benjamin Larman(Executive Officer, Director)inJoy M Nassif(Executive Officer, Director)in
BoardHerman Scholtz(Director)inCaroline Popper(Director)in
Board seatMatthew Hellauer· per SEC Form D · $7M raise · filed Aug 2025
Co-investorsIllumina VenturesTCP Venture Capital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.